Venetoclax for the Treatment of Chronic Lymphocytic Leukemia

  • Herbert EradatEmail author
Chronic Lymphocytic Leukemias (N Jain, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Chronic Lymphocytic Leukemias


Purpose of this Review

This review summarizes the role of BCL-2 in the pathogenesis of CLL, and the clinical data evaluating safety and efficacy of venetoclax, in treatment of patients with CLL, in the context of other available targeted agents.

Recent Findings

Venetoclax, alone or in combination with other targeted agents results in high rate of durable responses and undetectable measurable residual disease. Venetoclax maintains activity across all clinical and biologic subgroups, including those with high risk disease, including CLL with chromosome 17p deletion. TLS risk can be mitigated with risk stratification and five-week administration ramp-up schedule.


Venetoclax, a novel, orally bioavailable inhibitor of BCL-2 has demonstrated substantial clinical activity in the treatment of CLL. In combination with other targeted agents it can induce high disease response rates and potentially lead to MRD-negative durable remissions.


CLL Venetoclax BCL-2 



Bruton’s tyrosine kinase


Chronic lymphocytic leukemia


Overall survival


Partial remission


Progressive disease


Progression free survival


Relapsed or refractory


Independent review committee


Minimal residual disease


Phosphatidylinositol-3 kinase


Immunoglobulin heavy chain variable region


Tumor lysis syndrome


Compliance with Ethical Standards

Conflict of Interest

Herbert Eradat declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences USA. 2002;99:15524–9.CrossRefGoogle Scholar
  2. 2.
    Bullrich F, Fujii H, Calin G, Mabuchi H, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Research. 2001;61(18):6640–8.Google Scholar
  3. 3.
    Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, Grandér D, et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene. 1997;15:2463–73.CrossRefGoogle Scholar
  4. 4.
    Strasser A, Cory SA, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other disease. EMBO J. 2011;30:3667–83.CrossRefGoogle Scholar
  5. 5.
    Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312(21):2276.CrossRefGoogle Scholar
  6. 6.
    Institute, National Cancer. Surveillance epidemiology and end results cancer statistics review (SEER) database. 2016.Google Scholar
  7. 7.
    Guieze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015;126:445–53.CrossRefGoogle Scholar
  8. 8.
    Bron JR, Halleck MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? American Society of Clinical Oncology Education Book. 2016;35:387–98.CrossRefGoogle Scholar
  9. 9.
    Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.Google Scholar
  10. 10.
    The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncology. 2016;17:779–90.CrossRefGoogle Scholar
  11. 11.
    Zenz T, Kroeber A, Schere K, Habe S, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322–9.CrossRefGoogle Scholar
  12. 12.
    Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.CrossRefGoogle Scholar
  13. 13.
    Byrd JC, Furman RR, Coutre SE, Burger JA, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506.CrossRefGoogle Scholar
  14. 14.
    Farooqui MZ, Valdez J, Martyr S, Aue G, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncology. 2015;16(2):169–76.CrossRefGoogle Scholar
  15. 15.
    Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440–3.CrossRefGoogle Scholar
  16. 16.
    Cimmino A, Calin GA, Fabbri M, Iorio MV, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences USA. 2005;102:13944–9.CrossRefGoogle Scholar
  17. 17.
    Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–9.CrossRefGoogle Scholar
  18. 18.
    Migliazza, A, Bosch, F, Komatsu, H, Cayanis, E, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. 2001, Vol. 97, pp. 2098–2104.Google Scholar
  19. 19.
    Roberts, AW, Huang, DCS. Targeting BCL 2 with the BH3 mimetics: Basic science and clinical application of Venetoclax in chronic lymphocytic leukemia and related B cell malignancies. 2017, Vol. 101, pp. 89–98.Google Scholar
  20. 20.
    Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of BH three my medic BCL-2 inhibitor Nvidia clocks ABT 263 with or without rituximab, in previously untreated B cell chronic lymphocytic leukemia. Leukemia and Lymphoma. 2015;56:2826–33.CrossRefGoogle Scholar
  21. 21.
    Salem AH, Agarwal SK, Dunbar M, Enschede SL, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-hodgkin lymphoma. Journal of Clinical Pharmacology. 2017;57(4):484–92.CrossRefGoogle Scholar
  22. 22.
    Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs. 2017;28(8):911–4.CrossRefGoogle Scholar
  23. 23.
    Salem AH, Dunbar M, Agarwa SK. Pharmacokinetics of venetoclax and patient with 17p deletion chronic lymphocytic leukemia. Anti-Cancer Drugs. 2017;28:911–4.CrossRefGoogle Scholar
  24. 24.
    Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL-2 with venetoclax in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 2016;374:311–22.CrossRefGoogle Scholar
  25. 25.
    Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with Ibrutinib in chronic lymphocytic leukemia. Clinical Cancer Research. 2015;21(16):3705–15.CrossRefGoogle Scholar
  26. 26.
    Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia and Lymphoma. 2017;10:2287–97.CrossRefGoogle Scholar
  27. 27.
    Fischer K, Al-Sawaf O, Fink AM, Dixon M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702–5.CrossRefGoogle Scholar
  28. 28.
    Kater AP, Kersting S, van Norden Y, Dubois J, et al. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Adnavces. 2018;2(24):3566–71.CrossRefGoogle Scholar
  29. 29.
    Rogers KA, Huang Y, Ruppert AS, Awan FT, et al. Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–72.CrossRefGoogle Scholar
  30. 30.
    Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:1215–28.CrossRefGoogle Scholar
  31. 31.
    Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78.CrossRefGoogle Scholar
  32. 32.••
    Seymour JF, Ma S, Brander DM, Choi M, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. The Lancet oncology. 2017;18:230–40. Findings from this study established superior safety and efficacy of therapy with venetoclax and rituximab for patients with relapsed or refractory CLL, in comparison to cytotoxic chemoimmunotherapy with bendamustine and rituximab. For the first time, these MURANO data findings can lead to a paradigm shift in the treatment of patients with relapsed disease, utilizing a defined 2-year course of therapy that induces high response rates, with durable disease control. CrossRefGoogle Scholar
  33. 33.
    Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. British Journal of Hematology. 2015;170:669–78.CrossRefGoogle Scholar
  34. 34.
    Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215–24.CrossRefGoogle Scholar
  35. 35.
    Rogers KA, Huang Y, Ruppert AS, Awan FT, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–72.CrossRefGoogle Scholar
  36. 36.•
    Jones JA, Mato AR, Wierda WG, Davids MS, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology. 2018;19(1):65–75. Findings in this study established the efficacy and safety of venetoclax after BTK inhibition, and provide clinical guidance on optimal sequencing of these agents. CrossRefGoogle Scholar
  37. 37.
    Coutre S, Choi M, Furman RR, Eradat H, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704–11.CrossRefGoogle Scholar
  38. 38.
    Mato AR, Hill BT, Lamanna N, Barr PM, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Annals of Oncology. 2017;28(5):1050–6.CrossRefGoogle Scholar
  39. 39.
    Anderson MA, Tam C, Lew T, Juneja S, Juneja M, Westerman D, et al. Clinical and pathological features and outcomes of progression of CLL on BCL-2 inhibitor venetoclax. Blood. 2017;129:3362–70.Google Scholar
  40. 40.
    Parikh SA, Kay NE, Shanafelt TD. How we treat Richter’s syndrome. Blood. 2014;123(11):1647–57.CrossRefGoogle Scholar
  41. 41.
    Roberts AW, Seymour JF, Eichhorst B, et al. Pulled multi-trial analysis of venetoclax efficacy in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstacts, Blood. 2016;128(22):3230.Google Scholar
  42. 42.
    Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016–24.CrossRefGoogle Scholar
  43. 43.
    Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727–32.CrossRefGoogle Scholar
  44. 44.
    Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.David Geffen School of Medicine at UCLAUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations